Inozyme Pharma, Inc.
INZY · NASDAQ
3/31/2025 | 12/31/2024 | 9/30/2024 | 6/30/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $20,379 | $22,473 | $19,890 | $21,758 |
| G&A Expenses | $5,409 | $4,698 | $4,961 | $5,907 |
| SG&A Expenses | $5,409 | $4,698 | $4,961 | $5,907 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $1,900 | $0 | $0 | $0 |
| Operating Expenses | $27,688 | $27,171 | $24,851 | $27,665 |
| Operating Income | -$27,688 | -$27,171 | -$24,851 | -$27,665 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$351 | $97 | $281 | $632 |
| Pre-Tax Income | -$28,039 | -$27,074 | -$24,570 | -$27,033 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$28,039 | -$27,074 | -$24,570 | -$27,033 |
| % Margin | – | – | – | – |
| EPS | -0.44 | -0.43 | -0.39 | -0.44 |
| % Growth | -2.3% | -10.3% | 11.4% | – |
| EPS Diluted | -0.44 | -0.43 | -0.39 | -0.44 |
| Weighted Avg Shares Out | 64,279 | 62,812 | 63,277 | 61,944 |
| Weighted Avg Shares Out Dil | 64,279 | 62,812 | 63,277 | 61,944 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1,117 | $1,484 | $1,778 | $2,030 |
| Interest Expense | $1,406 | $1,422 | $1,416 | $1,395 |
| Depreciation & Amortization | $176 | $177 | $195 | $188 |
| EBITDA | -$26,457 | -$25,475 | -$22,959 | -$25,450 |
| % Margin | – | – | – | – |